From supply challenges surrounding COVID-19 to regulatory changes and innovations, the year 2022 is set to be an interesting year for biopharma manufacturing companies around the world.

Here, Bill Vincent, Founder and Executive Chairman at Genezen provides his insights into the top biopharma trends we can expect to see in 2022. He also highlights the impact of regulatory changes on serum use for cell growth and the potential of stable producer cell lines throughout cell and gene therapy manufacturing.

Read the full article: Key challenges for biopharmaceutical manufacturing 2022